- Home
- SLGL vs TP Comparison
SLGL vs TP Comparison
Compare SLGL & TP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$63.06
Company Overview
Basic Information| Metric | SLGL | TP |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Israel | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 246.4M |
| IPO Year | 2016 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SLGL | TP |
|---|---|---|
| Price | $63.06 | $8.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | ★ 52.7K | 48.5K |
| Earning Date | 05-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.84 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.00 | $6.10 |
| 52 Week High | $97.97 | $12.14 |
Technical Indicators
Market Signals| Indicator | SLGL | TP |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 51.67 |
| Support Level | $62.21 | $8.10 |
| Resistance Level | $67.85 | $9.36 |
| Average True Range (ATR) | 3.08 | 0.53 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 58.87 | 57.80 |
Price Performance
Historical Comparison SLGL
TP
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.